10 clinical trials to watch in the first half of 2022 (2023)

An article from 10 clinical trials to watch in the first half of 2022 (1)


Biotech stocks end 2021 with pullbacks. But positive results in breast cancer, schizophrenia and Alzheimer's could help reverse that fate.

Released on January 3, 2022 Updated January 6, 2022

Ben Fiedler chief editor

10 clinical trials to watch in the first half of 2022 (3)

A year ago, the biotech industry hit record highs. The successful development of vaccines and drugs against the coronavirus helped slow the pandemic and boosted investment in new companies, which went public at a record pace. An index of biotech stocks hit an all-time high.

But the momentum quickly faded. Clinical and regulatory backlash, as well as the prospect of US drug pricing reform, have weighed on companies large and small, driving share prices lower and widening the gap between industry performance and the broader market. Nearly 80% of 2021 IPO classes trade below asking price as new publicly traded biotechs struggle to gain footing, reports sayData from BioPharma Dive.

Positive clinical trial results — events that companies can use to influence investors, close deals and raise capital — could help turn the tide. There are many opportunities ahead: important studies in breast cancer, cystic fibrosis and ulcerative colitis are due to be presented in the first half of the year.

Here are 10 to watch:


Pfizer, Arena Pharmaceuticals


Ulcerative colitis

Type of treatment:

Small Molecule

Why it matters:

PfizersArena was acquired for $7 billion, one of the industry's biggest acquisitions of 2021, built largely on the promise of a single drug called etrasimod. After disappointing sales of the weight-loss drug, Arena has repositioned itself around the drug that has shown promise in several inflammatory diseases. Etrasimod works the same way as Zeposia, once Celgene's crown jewelGet a receiptNow sold by Bristol Myers Squibb.

Pfizer bet on Arena because it believed its drug was better and did so before major clinical trial results confirmed that belief -- surprising some Wall Street analysts. Those results will be published this year, starting with two trials testing Etrimod in ulcerative colitis.

Pfizer executives announced in a recent conference call that they reviewed blinded data from two studies, Elevate 12 and Elevate 52, and assumed etrasimod would be a commercial success. (Increase 12 results may be available first, according to the federal clinical trials database.)

Pfizer is counting on such results to boost its inflammatory disease business, which includes the drugs Xeljanz and abrocitinibSlowed down due to security concerns.


(Video) Top 10 Most Memorable Trial Moments of 2022 — Law&Crime Rewind

Sanofi, GlaxoSmithKline


coronavirus disease

Type of treatment:

protein vaccine


Why it matters:

The coronavirus pandemic has changed since 2020, when Sanofi and GlaxoSmithKline jointly developed a vaccine for COVID-19. The original strain of the coronavirus has given way to elusive variants that pose more difficult targets for vaccines being developed by companies such as Moderna, partners Pfizer and BioNTech. At the same time, booster vaccines are becoming increasingly important as they have proven to be the best defense against rapidly spreading Omicron variants and weakened immune protection.

These factors make Sanofi and GlaxoSmithKline attractive for potential roles in vaccine trials in 2022 and beyond, which have now been delayed several times. In December, the couple reported his shootingIt can significantly increase the concentration of antiviral antibodiesAmong people previously vaccinated with any of the four most commonly used vaccines. But they can't apply for approval until they show their vaccine can prevent COVID-19 in a large clinical trial -- a trial that's harder to do as more people get vaccinated or become infected.

Sanofi and GSK are expected to announce their results in early 2022. If the results are positive, their vaccine is based on proven technology and may help where other vaccines are not widely available.




Alzheimer's disease

Type of treatment:


Why it matters:

Can Aduhelm, the first new Alzheimer's drug in decades, really slow the mental and physical decline caused by the disease? Doctors, experts, and even FDA reviewers disagree.spark a conversationThat made the agency's decision to approve the drug one of the most controversial in its history.

In the face of conflicting clinical trial data, the FDA decided to approve Aduhelm based on its mode of action, creating a long-standing and unproven disease hypothesis. Later in 2022, results from Roche and Eisai could provide evidence for Aduhelm, its maker, Biogen and the FDA, or further challenge the drug's approval.

Aduhelm, Roche's gantenerumab and Eisai's lecanemab work by targeting protein clumps in the brain called amyloid. Over the past decade, clinical trials have failed due to a long line of precursors that somehow also target amyloid.

Beyond that, however, gantenerumab and lecanemab could show benefit, depending on the type of amyloid clumps targeted and more carefully tailored study designs. (Gantenerumab performed poorly in a previous study, but is being reevaluated at a higher dose.)

Eisai - Biogen's development partner for Aduhelm - hasApply for expedited approvalBased on preliminary data from the study, lecanemab showed that the treatment can clear amyloid in the brain. Meanwhile, Roche recently told the study's researchers that it would not seek fast-track approval for its drug.

Phase 3 data from the two companies is not expected until the second half of the year, although a Roche study is being announcedgraduation 1– Designation in the federal database for clinical trials was completed in May. In any case, these studies will be closely monitored throughout the year.

Meanwhile, Eli could quickly follow Lilly Roche and Eisai into a Phase 3 lead for Alzheimer's drug donanemab by mid-2023. Also the drug companyApply for expedited approvalBased on the amyloid reduction data, the FDA is expected to make a decision by the end of 2022.




cystic fibrosis

Type of treatment:

Small Molecule


(Video) Clinical Trial Trends 2022

Why they matter:

Gradually, Vertex Pharmaceuticals has blocked potential competitors for four of its key cystic fibrosis drugs, which now bring in nearly $7 billion a year. But biotech's toughest test may yet lie ahead.

Earlier this year, AbbVie was set to announce evidence-based results of a triple-drug combination with ingredients similar to Trikafta, Vertex's CF triplet and its best-selling drug. The program is part of AbbVie's long-term effort to challenge Vertex CF's leadership position. The pharmaceutical giant partnered with Galapagos NV for five years before deciding to acquire the Belgian biotech's cystic fibrosis portfolio in 2018, a move that surprised analysts at the time as some of the drugs had disappointed early results. The teacher was surprised.

But AbbVie has since worked to improve its drug mix, making changes to two of its three ingredients. Jeff Stewart, chief commercial officer, said in a conference call earlier this year that the company would like to see an "efficiency advantage" over the Trikafts, even a small one. Although AbbVie doesn't expect full results until late 2022, the company will announce some results publicly in the first quarter. Data fromTwo-drug planThe same is expected.

The results have important implications for Vertex as the company struggles to build a business beyond cystic fibrosis.contrite.




Breast cancer

Type of treatment:

Antibody-drug conjugates

Why it matters:

Gilead has invested over a decade and billions to become a major player in oncology, with mixed results. The company has won approval for three cancer drugs in the past four years, but sales are falling from its established HIV drugs.

Cancer drug Trodelvy aims to help change the narrative of Gilead, the number one reason for the biotech$21 billion was spentIn 2020, the drug's manufacturer, Immunomedics, was created.

Currently, Trodelvy is only approved for the treatment of advanced triple-negative breast cancer and a form of bladder cancer. For the drug to be the blockbuster that Gilead envisioned, Trodelvy must be successful in an ongoing Phase 3 trial called TROPiCS-02.

The study will compare Trodelvy with different types of chemotherapy in patients with HR-positive, HER2-negative breast cancer, which accounts for 60 to 70% of all breast cancer cases. Patients in the study experienced disease progression despite two to four prior treatments, including a relatively new breast cancer drug called a CDK 4/6 inhibitor.

Positive results in the first quarter of 2022 will be critical for Gilead. A win would give Trodelvy a $2 billion revenue opportunity, increase Gilead's stake by 5% to 8% and confirm the Immunomedics deal, wrote RBC Capital Markets analyst Brian Abrahams.





Type of treatment:

Small Molecule

Why it matters:

Developing new drugs to treat mental illness is notoriously difficult, so any promising drug is subject to intense scrutiny. A good example is the drug KarXT developed by Karuna Therapeutics. Exciting Results from the Phase 2 Schizophrenia TrialHe increased the company's capitalization by billionsAnd it is one of the most talked about drugs in this field.

KarXT combines the powerful antipsychotic xanomeline with a chemical called trospium, which is said to reduce potentially problematic side effects such as sedation and vomiting. Because of these problems, Eli Lilly developed and discontinued Xanomeline in the 1990s. But Karuna's drug showed few of these signs in interim trials, but had a measurable impact on schizophrenia symptoms.

This supports a reevaluation of xanomeline and other similar drugs that act on proteins in the nervous system called muscarinic receptors. A similar drug from Cerevel Therapeutics also shows promise. Karuna has since initiated further studies of KarXT, including a phase 2 study in Alzheimer's patients with psychosis.

Stifel analysts estimate that muscarinic drugs will be worth about $4 billion in the treatment of schizophrenia. So there's a lot to be said for Karuna's phase 3 trial called EMERGENT-2, which is expected to have results by mid-year. However, many promising neurological drugs have so far underperformed in late-stage trials, often due to an unexpectedly large placebo effect.


Intercept Pharmaceuticals


non-alcoholic steatohepatitis

Type of treatment:

Small Molecule

Why it matters:

Few biotechs have rallied faster than Intercept Pharmaceuticals, whose shares plummeted from more than $400 a share to less than $16 a share because of the turmoil surrounding opicholic acid, a drug used to treat fatty liver disease. NASH disease.

Intercept Support promotes early clinical outcomesPhase 3 of the REGENERATE study has been a clear successIn 2019, the company was positioned to commercialize the first treatment for NASH, a disease believed to affect millions of people in the United States. However, the FDA does not believe that the benefits outweigh the potential risks, which include cardiometabolic effects. the institutionAsk the Intercept for more dataFrom efforts leading to long delays,corporate restructuringand several senior executives resigned.

But the interception still has a chance to recover. Potential rivals such as Gilead, Genfit and NGM Biopharmaceuticals failed to capitalize on Intercept's mistake as NASH proved a tougher target than previously expected. Others, such as Madrigal Pharmaceuticals, are still awaiting Phase 3 results.

If REGENERATE's updated results are positive, Intercept could receive its first NASH drug approval. The results earlier this year are expected to include more safety data than Intercept's initial filing, as well as analysis of 18 months of liver biopsies from more than 500 patients.

Recent results will also be available from REVERSE, a study that enrolled NASH patients with liver cirrhosis but no symptoms yet. The overall data set should provide "long-awaited clarity on the viability of [obeticholic acid] in NASH," SVB Leerink analyst Thomas Smith wrote recently.

(Video) Trialled and Tested: Introducing clinical trials | Clinical Trials Day 2022


allogeneic therapy


large B-cell lymphoma

Type of treatment:

cell therapy


Why it matters:

The past year has been a challenging one for the field of so-called standard CAR-T therapies. It is well known that allogeneic therapy aims to be a more convenient alternative to the personalized cell therapies currently used to fight a variety of blood cancers. However, it has not yet been shown to be less resistant to more complex treatments. The biggest surprise, however, came in October when the FDAAllogenee Therapeutics clinical trial suspended, one of the leading companies in this field.

The move comes after researchers discovered a "chromosomal abnormality" in a patient treated with ALLO-501a, an approach adopted by Allogene to advance the lymphoma treatment. Although the clinical significance of this finding is unclear, the agency responded decisively by halting not only trials of ALLO-501a, but all of Allogene's other programs.

Since then, Allogene has been working with the FDA to determine whether gene editing was to blame in the preparation of its treatment. The company, in turn, downplayed the incident, and executives expressed surprise at the FDA's actions.

But the clinical lockdown nearly halved Allogene's share price and raised new questions about the standard treatment. Several analysts believe this year's results and the resumption of trials could have broad implications for allogeneic and other developers of standard cell therapies, many of which involve gene editing.


GlaxoSmithKline, Pfizer


Respiratory syncytial virus

Type of treatment:



(Video) Does NMN Work On Humans? An Overview Of All Clinical Trials

Why they matter:

The COVID-19 vaccine has garnered global attention over the past two years, becoming one of the most widely used and most profitable products in the history of the pharmaceutical industry. Fewer headlines reported a high-stakes race to develop a vaccine against another common and potentially deadly respiratory syncytial virus infection. Important clinical trial results are expected this year.

RSV is known to cause about 177,000 hospitalizations in older adults and 58,000 hospitalizations in children under five each year. The virus has proved a difficult target for pharmacists: efforts to develop a vaccine dating back to the 1960s have been unsuccessful. The only way to fight the infection is with antiviral therapy. Synthetic antibodies can also be used to prevent the diseases they cause.

That may change soon. GlaxoSmithKline, Pfizer and Johnson & Johnson have developed vaccines that train the body to recognize the viral proteins that RSV uses to infect human cells. All three vaccines are currently in late-stage trials. Pfizer and GlaxoSmithKline are expected to have preliminary Phase 3 data by mid-year, with J&J soon after.

The economic implications of these studies are significant. Cowen analysts predict that the RSV vaccine market will be worth nearly $10 billion by 2028.



Alnylam Pharmaceuticals



Type of treatment:

RNA interference


Why it matters:

One of the most surprising trial failures of 2021 occurred in the final week of a drug for transthyretin amyloidosis, a rare genetic condition that affects the heart.Not superior to placebo in phase 3 studyNeil Kumar, chief executive of drug developer BridgeBio, said in a statement that the results were "confusing", with shares falling nearly 80%. They are raising levels in the Alnylam Pharmaceuticals study, which is expected to provide data by mid-2022.

Alnylam's Onpattro was the first RNA interference drug to hit the market when the FDA approved it in 2018 for neurological damage associated with amyloid transthyretin (ATTR). Alnylam has since won approval for a number of other RNAi drugs, but Onpattro remains the best-selling drug. Key to its development was the demonstration that Onpattro could help ATTR patients with heart disease - a more rapidly progressive, deadlier and more common disease.

The APOLLO-B study was designed to do just that, and Alnylam has provided encouraging early results from the study. This year, Alnylam will report whether Onpattro can help patients outperform placebo in a trial measuring how far they can walk in six minutes after a year of treatment. This is the same benchmark that BridgeBio's drug failed, largely because placebo recipients did significantly better than in previous ATTR trials.

BridgeBio said it does not yet know why its drug is in short supply. But Alnylam shares fell more than 15 percent amid fears that the bar for success in the ATTR study may now be higher, Stifel analyst Paul Matteis said. Matteis wrote that Alnylam believes its drug should have a stronger effect because it works differently than similar drugs approved by BridgeBio and Pfizer.

Ned Pagliarulo contributed to this report.

Correction: This story has been updated to mention Roche's latest program related to gantenerumab and to correctly state the name of the study.

Filed under: Clinical tests

BioPharma Dive news delivered to your inbox

Receive a free daily newsletter read by industry experts

10 clinical trials to watch in the first half of 2022 (4)

Editor's Choice

  • Tieftauchgang

    Despite recent concerns about an aggressive FTC, analysts expect business to pick up again this year, with smaller acquisitions such as Ironwood's takeover of VectivBio, as well as larger mergers.

    Jacob Bell and Julia Heaven •Updated May 22, 2023

  • Discover trend lines ➔

    voltage line

    cell therapy

    Six CAR-T cell therapies are now approved in the United States, and their continued adoption is helping to fuel further research into next-generation approaches.

    Courtesy of BioPharma Dive staff

    (Video) The Comprehensive Map of Medicine


What are the clinical research trends for 2022? ›

In 2022, integrating innovative approaches into clinical trial workflows — including telehealth, artificial intelligence/machine learning, real-world data, hybrid models and other digital tools — will be essential to conducting more trials with fewer patients.

How many clinical trials in 2022? ›

Number of Registered Studies by Year (as of May 30, 2023)
Year First PostedStart of YearDuring Year
20 more rows

What are the most popular clinical trials? ›

Cancer treatments have the highest clinical trial volume
  • Cardiovascular & Circulatory Diseases. ...
  • Digestive Diseases. ...
  • Musculoskeletal Diseases. 38,607.
  • Infectious Diseases. 37,067.
  • Endocrinology & Metabolic Disease. 32,702.
  • Nervous System Diseases. 31,934.
  • Mental Health & Behavioral Disorders. 26,752.
  • Respiratory Diseases. 17,569.
Jan 17, 2023

Who is the largest CRO in the world? ›

As the largest CRO in the world, IQVIA operates in over 100 countries across the globe and brings together advances in data science, technology, and human science expertise, offering their clients an end-to-end clinical and commercial service.

What are the pharmaceutical trends for 2022? ›

In 2022, NLP, machine learning, and automation will be one of the fastest-growing pharma marketing trends as companies look to capitalize on consumer interest in health and well-being while abiding by regulatory guidelines.

What are the new trends in research? ›

One of the major trends in qualitative research is the use of online and mobile platforms to collect, analyze, and share data. These platforms can offer convenience, flexibility, and accessibility for both researchers and participants, especially in times of social distancing or travel restrictions.

Why do 90% of clinical trials fail? ›

Despite these significant investments in time and money, 90% of drug candidates in clinical trials fail. Whether because they don't adequately treat the condition they're meant to target or the side effects are too strong, many drug candidates never advance to the approval stage.

What is the Crispr Human Trials 2022? ›

In 2022, the first participants were dosed in a US trial using CRISPR to treat HIV. The experimental treatment uses CRISPR genome-editing molecules to target the HIV DNA sequence stored in the host cell genome.

Which clinical trial has 100 success rate? ›

A recent clinical trial involving 14 rectal cancer patients at Memorial Sloan Kettering Cancer Center in New York had an incredible 100% success rate. They were given an immunotherapy medication called “Dostarlimab.” 6 months later, the cancer was gone in every single patient.

What is the largest clinical trial ever done? ›

The polio vaccine trials were among the largest clinical trials ever performed. In the United States, over 600,000 school children were injected with either the vaccine or placebo. More than a million others participated as “observed” controls.

What is the largest CRO in the world 2023? ›

Top 10 CROs to Watch in 2023
  • ICON. ...
  • Vial Health Technology Inc. ...
  • IQVIA. ...
  • Labcorp. ...
  • Parexel. ...
  • PPD. ...
  • Syneos Health. ...
  • WuXi AppTec. WuXi PharmaTech was founded in China in 2000, and upon acquiring US-based AppTec Laboratory Services in 2008, WuXi AppTec was formed.

Which is the best CRO for operational excellence? ›

CTI was named the Top CRO for Operational Excellence, Responsiveness, and Technology for Access to Data. Winners of the awards are determined using primary market research conducted by ISR.

Is labcorp a CRO? ›

Labcorp Drug Development is a contract research organization (CRO) headquartered in Burlington, North Carolina, providing nonclinical, preclinical, clinical and commercialization services to pharmaceutical and biotechnology industries.

What are the big pharma trends for 2023? ›

Greater Adoption of AI and Machine Learning: AI and machine learning will play a significant role in the pharma industry in 2023. They will be used to develop more effective treatments, identify new drug targets, streamline clinical trials, plan sales strategies, and gain market insights.

What are the pharma trends in 2023? ›

A major trend for the pharmaceutical industry in 2023 will be the increased use of wearable devices in clinical trials. Wearable devices house biosensors that collect data that medical professionals can use to assess a patient's responses to a particular treatment or therapy during a clinical trial.

What is out of trend in pharmaceutical industry? ›

What is Out of Trend (OOT)? Out of trend is defined as a result of a sequence of the analytical results which conform to the specifications but not in the expected trend with respect to the initial or expected result. OOT reveals that there may be a problem with the analysis or the production process.

What are the top 5 trends? ›

5 Trends for 2020 (and 22 for 2022!)
  • GREEN PRESSURE. In 2020, consumers move from eco-status to eco-shame.
  • BRAND AVATARS. Human brands take powerful new form.
  • METAMORPHIC DESIGN. Consumers demand relevance as a service.
  • THE BURNOUT. Smart brands rush to help those burned by the pressures of modern life.

What are the 3 major trends? ›

There are three main types of trends: short-, intermediate- and long-term.

What are the four 4 categories of trends? ›

Entrepreneurs should observe at least four types of trends—economic, social, technological and regulatory—to identify business opportunities and grow their startups. By paying close attention to economic trends, they can identify areas that are ripe for new ideas.

What is the biggest barrier to clinical trials? ›

Misconceptions and a lack of awareness seem to be the most significant barriers for individuals who otherwise might be willing to participate in a clinical trial.

Why not to do clinical trial? ›

What are the Potential Risks of a Clinical Trial? The new treatment may cause serious side effects or be uncomfortable. The new treatment may not work, or it may not be better than the standard treatment.

What percentage of patients drop out of clinical trials? ›

Approximately 30% of patients drop out of clinical trials, resulting in heavy financial costs. On average, it costs $6,533 to recruit one patient to a clinical study, and the cost of replacing patients is even higher. The average cost to recruit a new patient if one is lost due to non-compliance is $19,533.

What disease is CRISPR getting rid of? ›

Scientists use CRISPR to edit DNA. If a harmful DNA variant causes a disease, scientists might be able to use CRISPR to fix the problem. They could use CRISPR to edit the gene by changing the DNA from the harmful variant to a healthy variant.

What diseases can CRISPR cure? ›

CRISPR technology has also been successful in treating a pediatric patient with T-cell acute lymphoblastic leukemia, showing feasibility of its use for cancer immunotherapy.

Is COVID vaccine CRISPR? ›

We are developing a CRISPR-based DNA-vaccine enhancer for COVID-19 that would radically reduce the timeline to develop vaccines against current and future viral threats.

What are the 5 types of clinical trials? ›

Types of clinical trials
  • Pilot studies and feasibility studies.
  • Prevention trials.
  • Screening trials.
  • Treatment trials.
  • Multi-arm multi-stage (MAMS) trials.
  • Cohort studies.
  • Case control studies.
  • Cross sectional studies.
Feb 1, 2022

What are the 3 main stages of drug testing? ›

There are three main stages of testing:
  • Preclinical drug trials - The drugs are tested using computer models and human cells grown in the laboratory. ...
  • Animal trials - Drugs that pass the first stage are tested on animals. ...
  • Human clinical trials - Drugs that have passed animal tests are used in clinical trials.

Why do most clinical trials never go to stage 3? ›

In summary, the main three reasons for drug failure during phase 3 of clinical trials is often due to a lack of supporting data around efficacy, safety and commercial viability. Without proof of efficacy and safety, a drug cannot be approved for market use.

What new drug has 100 success rate? ›

For the first time, an immunotherapy drug has generated a 100% remission rate for a specific form of rectal cancer. This promising study of 12 patients, which was led by Memorial Sloan Kettering Cancer Center (MSKCC), made headlines around the world and piqued the interest of cancer patients and casual observers alike.

Are clinical trials worth the risk? ›

Well-designed and well-performed clinical trials provide benefits to you while allowing you to help others by contributing to knowledge about new treatments or procedures. You gain access to new research treatments before they are widely available.

Do all clinical trials pay you? ›

Paid trial opportunities are not the norm, but for the ones that are compensated, rates can vary tremendously. Some trials offer payment for time and effort, while others simply reimburse travel costs or childcare. Typically, the rate of compensation will have to do with the phase of the trial.

Can you make a living from clinical trials? ›

Sometimes it might just be one overnight stay, but other times it could involve months of tests and follow-ups. It's worth knowing this before proceeding. Are clinical trials a good way to make money? Yes, despite some perhaps being a lot less enjoyable than others, they're a great way to make easy money.

What is the highest salary for a clinical trial manager? ›


What is the salary after clinical research in USA? ›

Salaries by years of experience in the United States
Years of experiencePer year
1 to 2 years$67,800
3 to 5 years-
6 to 9 years$103,167
More than 10 years-
1 more row

What is the oldest clinical trial? ›

1747: James Lind and Scurvy Trial

James Lind is considered the first physician to have conducted a controlled clinical trial of the modern era. Dr Lind (1716-94), whilst working as a surgeon on a ship, was appalled by the high mortality of scurvy amongst the sailors.

Which country has the most clinical trials? ›

In numbers: The 10 countries conducting the most clinical trials since 2008
  • United States: 148,736.
  • France: 30,080.
  • Canada: 24,581.
  • China: 23,509.
  • Germany: 22,215.
  • United Kingdom: 21,163.
  • Spain: 16,492.
  • Italy: 16,140.
Apr 8, 2022

How many clinical trials before a drug is approved? ›

The FDA typically requires Phase 1, 2, and 3 trials to be conducted to determine if the drug or device can be approved for further use. If researchers find the intervention to be safe and effective after the first three phases, the FDA approves it for clinical use and continues to monitor its effects.

What is the projected 2028 CRO market size? ›

Facts and Factors estimate that the global contract research organization (CRO) market would grow 6.4% to USD 65.5 billion by 2028 from USD 52.1 billion in 2021.

How big is the CRO industry? ›

According to a Comprehensive Research Report by Market Research Future (MRFR), "Contract Research Organization Market Information By Segment, Clinical Trial Phase, End Users - Forecast till 2030", the market size was valued at USD 39.69 Billion in 2021 and is projected to grow from USD 45.53 Billion in 2022 to USD ...

What are the 4 stages of operational excellence? ›

To consistently deliver excellent service and be a true “Center of Excellence” the operation must master the four phases of excellence: essentials, effectiveness, efficiency, and excellence. Each phase must be mastered before moving to the next phase.

What are the four operational excellence focus areas? ›

“Operational Excellence is made up of four main categories. They include strategy deployment, performance management, high performance work teams, and process excellence,” notes Peter Peterka, CEO of training company Global Six Sigma and Chairman of the International Society of Six Sigma Professionals.

What is Eagle Award for Best CRO? ›

The Eagle Award is a highly regarded industry honor from the Society for Clinical Research Sites (SCRS) that recognizes the top clinical research organization (CRO) for exemplifying a site-focused approach to clinical trial management.

Is Quest Diagnostics a CRO? ›

As the world's leading provider of diagnostic services and lab data, Quest Diagnostics offers Pharmaceutical Organizations and Contract Research Organizations (CROs) comprehensive drug development solutions.

Which CRO did LabCorp buy? ›

In 2014, Labcorp acquired CRO Covance for about $5.6 billion. This made the combined company a provider of clinical diagnostic testing and a full-service drug development organization.

Is Merck a CRO? ›

While Contract Research Organizations (CROs) conducting Merck-sponsored trials may use their own procedures, these procedures are reviewed and approved by Merck to ensure they meet regulatory requirements and adhere to Merck's clinical trials ethical principles. Merck also maintains oversight of CRO activities.

What is the future of clinical research? ›

Future trials would be based on artificial intelligence (AI), machine learning, and deep neural networks to improve drug discovery, interpretation of images, streamlining electronic medical record data, and improving trial workflow, and adapted to recent advances in immunology, precision medicine, and immunology.

What is the impact factor of clinical research 2022? ›

Journal's Impact IF Trend
YearJournal's Impact IF
YearJournal's Impact IF
2 more rows

What is the impact factor of journal of clinical trials 2022? ›

9 more rows

What is the impact factor of Advances in Clinical and Experimental Medicine 2022? ›

The 2022-2023 Journal's Impact IF of Advances in Clinical and Experimental Medicine is 1.736, which is just updated in 2023.

What is the biggest challenge in clinical research? ›

Patient recruitment, including patient retention and population diversity, tops the list of challenges that 55% of respondents face.

What is the highest salary in clinical research? ›

Highest salary that a Senior Clinical Research Associate can earn is ₹13.0 Lakhs per year (₹1.1L per month). How does Senior Clinical Research Associate Salary in India change with experience?

How COVID changed clinical research? ›

The COVID-19 pandemic has not only re-emphasised the importance of well designed randomised clinical trials but also highlighted the need for large-scale clinical trials structured according to a master protocol in a coordinated and collaborative manner.

What is the impact factor 2022 critical care medicine? ›

The 2022-2023 Journal's Impact IF of Critical Care Medicine is 9.296, which is just updated in 2023.

What is the impact factor for pharmaceuticals 2022? ›

The 2022-2023 Journal's Impact IF of Pharmaceuticals is 5.215, which is just updated in 2023.

What is considered an imp? ›

Regulation (EU) No 536/2014 Article 2 (5) defines an IMP as “a medicinal. 48. product which is being tested or used as a reference, including as a placebo, in a. 49. clinical trial”.

What is the highest impact factor journal 2022? ›

The following are the top 10 highest impact factors journals in 2022:
Apr 2, 2023

What is the impact factor of journal of inflammation 2022? ›

The 2022-2023 Journal's Impact IF of Journal of Inflammation is 6.283, which is just updated in 2023.


1. Edmond man says cheap drug for dogs cured his cancer
(KOCO 5 News)
2. FOX Virginia News at 10: Clinical Trials
(Advertise with CBS19 - ABC Virginia - FOX Virginia)
3. Obesity, Diabetes, Cancer and You | Dr. Peter Attia | EP 360
(Jordan B Peterson)
4. First In Human EP1 (1/6) | The Background to NIH's Clinical Research
(DCODE by Discovery)
5. Elon Musk REVEALS Neuralink's FIRST Human Trial in 2022
(Tech Central)
6. 'Tumors just vanished': Cancer patients now in remission after drug trial


Top Articles
Latest Posts
Article information

Author: Lidia Grady

Last Updated: 02/08/2023

Views: 6449

Rating: 4.4 / 5 (65 voted)

Reviews: 80% of readers found this page helpful

Author information

Name: Lidia Grady

Birthday: 1992-01-22

Address: Suite 493 356 Dale Fall, New Wanda, RI 52485

Phone: +29914464387516

Job: Customer Engineer

Hobby: Cryptography, Writing, Dowsing, Stand-up comedy, Calligraphy, Web surfing, Ghost hunting

Introduction: My name is Lidia Grady, I am a thankful, fine, glamorous, lucky, lively, pleasant, shiny person who loves writing and wants to share my knowledge and understanding with you.